Literature DB >> 272946

Acute leukemia after chemotherapy (melphalan).

N Einhorn.   

Abstract

During the years 1966-1973 474 patients with ovarian carcinoma were treated with melphalan. Of these, 48 patients received at least 300 mg melphalan and survived at least 3 years; four cases of acute leukemia were found among these 48 patients. All cases belonged to a group of 12 cases receiving 800 mg melphalan or more.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 272946     DOI: 10.1002/1097-0142(197802)41:2<444::aid-cncr2820410210>3.0.co;2-8

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  8 in total

1.  Cyclophosphamide in chronic active hepatitis.

Authors:  R Althouse; J E Huff; L Tomatis; J D Wilbourn
Journal:  Br Med J       Date:  1979-06-16

2.  Myelosuppression in polycythemia vera: chemotherapy or radiotherapy?

Authors:  Y Najean; C Dresch
Journal:  Blut       Date:  1982-01

3.  [Analysis of prognostic factors in plasmacytoma].

Authors:  W Gassmann; T Haferlach; N Schmitz; W Kayser; H H Euler; J Drews; H Löffler
Journal:  Klin Wochenschr       Date:  1984-10-01

4.  Persistence of chromosome rearrangements in peripheral lymphocytes from patients treated with melphalan for ovarian carcinoma.

Authors:  B Lambert; K Holmberg; N Einhorn
Journal:  Hum Genet       Date:  1984       Impact factor: 4.132

5.  Low intensity vibration mitigates tumor progression and protects bone quantity and quality in a murine model of myeloma.

Authors:  Gabriel M Pagnotti; M Ete Chan; Benjamin J Adler; Kenneth R Shroyer; Janet Rubin; Steven D Bain; Clinton T Rubin
Journal:  Bone       Date:  2016-06-02       Impact factor: 4.398

6.  Myeloid leukaemia following therapy for a first primary cancer.

Authors:  A Nandakumar; S Davis; S Moolgavkar; R P Witherspoon; S M Schwartz
Journal:  Br J Cancer       Date:  1991-05       Impact factor: 7.640

Review 7.  Chemically induced leukemia in humans.

Authors:  R H Adamson; S M Seiber
Journal:  Environ Health Perspect       Date:  1981-06       Impact factor: 9.031

8.  Risk of leukaemia in ovarian tumour and breast cancer patients following treatment by cyclophosphamide.

Authors:  J F Haas; B Kittelmann; W H Mehnert; W Staneczek; M Möhner; J M Kaldor; N E Day
Journal:  Br J Cancer       Date:  1987-02       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.